Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test outsmart prostate cancer?

NCT ID NCT06872619

Knowledge-focused Sponsor: Wren Laboratories LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This registry study is collecting blood samples and health data from 1,000 people being evaluated for prostate cancer. The goal is to test the accuracy of a new blood-based test called PROSTest, which looks for genetic signals of prostate cancer activity. Researchers hope this test could help detect the disease, monitor its progression, and predict how well different treatments might work. The study is open to all patients undergoing evaluation for prostate cancer and will follow their outcomes over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PROSTest, a blood-based test that analyzes circulating prostate cancer transcripts
What this could lead to
If successful, this registry could help validate a simple blood test that detects prostate cancer activity, recurrence, or treatment failure earlier and more accurately than current methods.
What could go wrong
This is an observational registry, not a treatment trial, so it won't directly test a new therapy. The biomarker's accuracy and usefulness will depend on long-term data collection and may not prove reliable across all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a histologically confirmed diagnosis of a prostate cancer

Ages

45 to 100 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All subjects Exclusion Criteria: * Female

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgen deprivation therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma pleomorphic adenoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgen deprivation therapy Chemotherapy Prostate biopsy Prostate cancer (adenocarcinoma) Prostatectomy PSA Radioligand

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Munster

    Münster, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.